When should clomiphene citrate be prescribed to a man with secondary hypogonadotropic hypogonadism, low or borderline low testosterone, and a desire to preserve fertility?

When to Prescribe Clomiphene to Men

Prescribe clomiphene citrate to men with secondary (hypogonadotropic) hypogonadism who desire fertility preservation, as it can normalize testosterone levels while maintaining spermatogenesis, unlike testosterone therapy which suppresses the HPG axis and compromises fertility. 1

Primary Indication: Secondary Hypogonadism with Fertility Concerns

The most critical distinction is identifying secondary hypogonadism (low testosterone with low or low-normal LH/FSH) rather than primary hypogonadism. For secondary hypogonadism patients seeking fertility, gonadotropin therapy (hCG/FSH) is the guideline-recommended standard, but clomiphene represents an off-label alternative that can achieve both testosterone normalization and fertility preservation 1.

Key Diagnostic Requirements Before Prescribing:

• Confirmed hypogonadism: Two separate early morning total testosterone levels <300 ng/dL (or <10.4 nmol/L) with consistent symptoms 1
• Low or low-normal LH levels: This confirms secondary (hypogonadotropic) rather than primary hypogonadism 2
• Fertility preservation desired: This is the primary reason to choose clomiphene over testosterone therapy 1, 2
• Adequate testicular volume: Mean testicular volume ≥14 mL predicts better response (HR 2.2, p<0.01) 3
• Baseline LH ≤6 IU/mL: This predicts robust response (HR 3.5, p<0.001) 3, 4

Clinical Algorithm for Clomiphene Use

Step 1: Confirm Eligibility

• Verify secondary hypogonadism (low T + low/normal LH)
• Exclude contraindications to testosterone therapy OR patient desires fertility
• Measure baseline: total T, free T, LH, FSH, estradiol, prolactin
• Perform testicular exam and measure testicular volume
• Consider semen analysis if fertility is a concern 2

Step 2: Identify Ideal Candidates

Best responders have:

• Testicular volume ≥14 mL 3
• Baseline LH ≤6 IU/mL 3, 4
• Higher baseline estradiol levels (predicts testosterone response, OR 1.06) 5
• Younger age (mean age in successful studies: 29-46 years) 6, 3

Step 3: Dosing Strategy

• Start: 25 mg every other day 6
• Target: Testosterone 550 ± 50 ng/dL 6
• Titrate to 50 mg every other day if needed (70% of patients achieve target on 25 mg dose) 6
• Reassess at 6-8 weeks: Check total T, free T, LH, FSH 7

Step 4: Expected Outcomes

Testosterone normalization:

• 91% of men achieve T ≥3.5 ng/mL (350 ng/dL) 5
• Mean increase: 1.7 ng/mL (median) to 4.6 ng/mL 5
• Alternative data shows increase from 179 ng/dL to 467 ng/dL 3

Fertility outcomes:

• 71% show some sperm concentration improvement 5
• However, 29% experience paradoxical decline in sperm count 5
• When combined with hCG, 47.4% achieve sperm in semen at 12 months, though most sperm are deformed 8
• Set realistic expectations: Improvements are modest and fertility outcomes are unpredictable 5

Symptom improvement:

• 67% report subjective improvement in hypogonadal symptoms 7
• Aging Males Symptoms scores decline significantly over 1 year 4
• Sexual dysfunction may not improve significantly 4

Critical Caveats and Pitfalls

FDA Status Warning

Clomiphene is NOT FDA-approved for male hypogonadism. The FDA label explicitly states: "There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene" 9. This is strictly off-label use.

When NOT to Use Clomiphene

• Primary hypogonadism (elevated LH/FSH): These patients cannot respond to clomiphene as their testes are already maximally stimulated 1
• No fertility concerns: Testosterone therapy is first-line and guideline-recommended 1
• Severe hypogonadism requiring rapid symptom relief: Testosterone therapy works faster
• Pituitary tumors or hyperprolactinemia: Address underlying pathology first 2

Safety Considerations

Clomiphene appears safer than testosterone therapy:

• Significantly lower rates of hypertension (6.04% vs 10.48%), stroke (0.52% vs 1.43%), coronary artery disease (1.51% vs 2.26%), polycythemia (1.07% vs 2.22%), and all-cause mortality (1.83% vs 10.13%) compared to TRT 10
• Minimal side effects: Transient nipple tenderness reported in isolated cases 7
• No major adverse events in long-term follow-up (mean 19 months) 6

Monitoring Protocol

• Initial: Recheck hormones at 6-8 weeks 7
• Maintenance: Measure testosterone/gonadotropins twice yearly once target achieved 6
• Semen analysis: If fertility is the goal, check at 6-12 months 5, 8
• Duration: Long-term use appears safe; studies show efficacy up to 19 months 6, 4

Practical Considerations

Clomiphene works by blocking estrogen receptors at the hypothalamus and pituitary, increasing GnRH and gonadotropin secretion, which stimulates testicular testosterone production and spermatogenesis. This physiological mechanism preserves the HPG axis, unlike exogenous testosterone which suppresses it 1, 10.

The 2025 EAU guidelines prioritize gonadotropins (hCG/FSH) as standard therapy for secondary hypogonadism with fertility concerns 1, but clomiphene offers a more convenient oral alternative with comparable testosterone outcomes, though fertility results are less predictable than with gonadotropins 5, 8.

For men without fertility concerns, testosterone therapy remains the guideline-recommended first-line treatment 1. The 2018 AUA guideline acknowledges clomiphene as an option for fertility preservation but does not provide strong recommendations due to limited evidence 2.